Intelligent Bio Solutions FY26 net loss widens to $12.47 million; revenue rises 38% to $4.2 million

Reader installed base climbed 22% to 1,886 units; consumable cartridges rose 35% to 106,500 units.

The company said it completed clinical data collection for its FDA 510(k) program; submission remains on track for the second half of calendar 2026.

Intelligent Bio Solutions posted fiscal 2026 revenue of $4.22 million, up 38% year-over-year.

Gross profit more than doubled to $2.05 million; gross margin widened 7.78 percentage points to 48.63%.

Operating loss widened to $12.61 million; net loss attributable to shareholders widened to $12.43 million.